| Apixaban versus warfarin in patients with atrial fibrillation CB Granger, JH Alexander, JJV McMurray, RD Lopes, EM Hylek, ... New England Journal of Medicine 365 (11), 981-992, 2011 | 11148 | 2011 |
| Apixaban with antiplatelet therapy after acute coronary syndrome JH Alexander, RD Lopes, S James, R Kilaru, Y He, P Mohan, DL Bhatt, ... New England Journal of Medicine 365 (8), 699-708, 2011 | 1345 | 2011 |
| Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial JD Easton, RD Lopes, MC Bahit, DM Wojdyla, CB Granger, L Wallentin, ... The Lancet Neurology 11 (6), 503-511, 2012 | 378 | 2012 |
| Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other … G Flaker, RD Lopes, SM Al-Khatib, AG Hermosillo, SH Hohnloser, B Tinga, ... Journal of the American College of Cardiology 63 (11), 1082-1087, 2014 | 350 | 2014 |
| Myocardial contractile response to nitric oxide and cGMP P Mohan, DL Brutsaert, WJ Paulus, SU Sys Circulation 93 (6), 1223-1229, 1996 | 345 | 1996 |
| Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised … RD Lopes, SM Al-Khatib, L Wallentin, H Yang, J Ansell, MC Bahit, ... The Lancet 380 (9855), 1749-1758, 2012 | 268 | 2012 |
| Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban—an oral, direct and selective factor Xa inhibitor RC Becker, H Yang, Y Barrett, P Mohan, J Wang, L Wallentin, ... Journal of thrombosis and thrombolysis 32, 183-187, 2011 | 185 | 2011 |
| High-sensitivity troponin I for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and other Thromboembolic Events in … Z Hijazi, A Siegbahn, U Andersson, CB Granger, JH Alexander, D Atar, ... Circulation 129 (6), 625-634, 2014 | 155 | 2014 |
| Quantification of apixaban's therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose TA Leil, Y Feng, L Zhang, A Paccaly, P Mohan, M Pfister CliniCal pharmaCology & TherapeuTiCs 88 (3), 375-382, 2010 | 113 | 2010 |
| The cardiac endothelium: functional morphology, development, and physiology DL Brutsaert, GW De Keulenaer, P Fransen, P Mohan, GL Kaluza, ... Progress in cardiovascular diseases 39 (3), 239-262, 1996 | 89 | 1996 |
| Myocardial performance is modulated by interaction of cardiac endothelium derived nitric oxide and prostaglandins P Mohan, DL Brutsaert, SU Sys Cardiovascular research 29 (5), 637-640, 1995 | 74 | 1995 |
| Effect of apixaban, an oral and direct factor Xa inhibitor, on coagulation activity biomarkers following acute coronary syndrome RC Becker, JH Alexander, LK Newby, H Yang, Y Barrett, P Mohan, ... Thrombosis and haemostasis 104 (11), 976-983, 2010 | 71 | 2010 |
| APPRAISE Steering Committee and Investigators. Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome … JH Alexander, RC Becker, DL Bhatt, F Cools, F Crea, M Dellborg, KA Fox, ... Circulation 119 (22), 2877-2885, 2009 | 69 | 2009 |
| Positive inotropic effect of nitric oxide in myocardium P Mohan, SU Sys, DL Brutsaert International journal of cardiology 50 (3), 233-237, 1995 | 56 | 1995 |
| Asymmetric and symmetric dimethylarginine predict outcomes in patients with atrial fibrillation: an ARISTOTLE substudy JD Horowitz, R De Caterina, T Heresztyn, JH Alexander, U Andersson, ... Journal of the American College of Cardiology 72 (7), 721-733, 2018 | 43 | 2018 |
| Cardiovascular safety of vardenafil, a potent, highly selective PDE-5 inhibitor in patients with erectile dysfunction; an analysis of five placebo-controlled clinical trials. RA Kloner, P Mohan, C Norenberg, K Pomerantz, T Segerson, SP Glasser Pharmacotherapy 22 (10), 1371-1371, 2002 | 36 | 2002 |
| Development of apixaban: a novel anticoagulant for prevention of stroke in patients with atrial fibrillation MS Hanna, P Mohan, R Knabb, E Gupta, C Frost, JH Lawrence Annals of the New York Academy of Sciences 1329 (1), 93-106, 2014 | 33 | 2014 |
| Apixaban decreases coagulation activity in patients with acute deep-vein thrombosis YC Barrett, J Wang, R Knabb, P Mohan Thrombosis and haemostasis 105 (01), 181-189, 2011 | 29 | 2011 |
| Cardiovascular safety of vardenafil in patients receiving antihypertensive medications: a post-hoc analysis of five placebo-controlled clinical trials RA Kloner, P Mohan, T Segerson, M Thibonnier, C Norenberg, ... Journal of the American College of Cardiology 41 (6S1), 276-277, 2003 | 28 | 2003 |
| Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial C Granger, JH Alexander, M Hanna, J Wang, P Mohan, J Lawrence, ... Eur Heart J 33 (suppl 1), 685-6, 2012 | 26 | 2012 |